Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-100, a first in class compound with the ability to block a cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. It also develops personalised medicine approaches to cancer, including targeted and cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Metrics to compare | PTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.8x | −5.1x | −0.5x | |
PEG Ratio | −0.53 | −0.10 | 0.00 | |
Price/Book | 3.7x | 3.5x | 2.6x | |
Price / LTM Sales | 9.8x | 14.3x | 3.2x | |
Upside (Analyst Target) | 325.6% | 317.0% | 38.8% | |
Fair Value Upside | Unlock | −9.9% | 5.4% | Unlock |